Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher, Massachusetts, Lexington Beloud

@wfmz.com · 1 hour

Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher

Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher

The FDA has approved Partner Therapeutics' BIZENGRI (zenocutuzumab-zbco) as the first targeted therapy for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring NRG1 ...

Read more Wfmz.com